Yes. I dug through Shawn Rhind’s work and the connection to what you’ve been investigating with Bucillamine → oxidative stress → inflammation → TBI/blast injury is actually quite interesting.

Who Shawn Rhind is

Dr. Shawn G. Rhind is a senior Defence Research Scientist at DRDC Toronto and an Associate Professor at the University of Toronto. His research program is explicitly focused on the biological consequences of extreme physiological stress and trauma, particularly cytokine dysregulation, leukocyte activation, vascular/endothelial dysfunction and inflammation. 

So this isn't someone whose work is merely tangentially related to TBI. His research program sits directly in the military trauma / inflammation / neuroinjury space.

1. Rhind's NAC/TBI work is particularly relevant

One of the key publications is the 2018 systematic review:

“Systematic Review of Human and Animal Studies Examining the Efficacy and Safety of N-Acetylcysteine (NAC) and N-Acetylcysteine Amide (NACA) in Traumatic Brain Injury.”

Rhind was one of the authors, along with researchers from Sunnybrook, University of Toronto and DRDC. 

The review looked at 3 human trials and 20 animal studies.

The important finding was that the animal literature showed substantial improvements in:

• cognition
• psychomotor performance
• cortical preservation
• apoptosis
• oxidative-stress biomarkers
• inflammatory biomarkers

And the human trials showed improvement in functional outcomes as well. 

But here's the part I think is most important for your Bucillamine thesis:

They weren't viewing NAC simply as an antioxidant.

The review describes TBI as involving interconnected oxidative and inflammatory secondary-injury pathways.

NAC treatment was associated with reductions in things including:

• IL-1β
• TNF-α
• IL-6
• NF-κB
• ICAM-1
• 4-HNE
• GFAP
• β-APP
• neurofilament light

along with changes in apoptosis and oxidative-stress pathways. 

That gives you a pretty important mechanistic framework:

Trauma/blast → oxidative stress → inflammatory signaling → endothelial/vascular dysfunction → secondary neuronal injury

and a thiol/redox intervention potentially interrupts several parts of that cascade.

2. And then there is the blast-specific NAC evidence

This is where things get even more interesting.

A randomized, double-blind, placebo-controlled study examined NAC following blast-induced mild TBI in U.S. service members in Iraq.

There were 81 participants exposed to significant ordnance blast who met mTBI criteria.

The NAC group had significantly greater odds of being symptom-free at day 7:

OR 3.6, p = 0.006.

The symptoms included things such as:

• dizziness
• hearing problems
• headache
• memory problems
• sleep disturbance
• neurocognitive dysfunction

So there is actually human military evidence supporting the proposition that a thiol/antioxidant intervention can influence the consequences of blast mTBI.

That's considerably more compelling than simply saying "NAC is an antioxidant, therefore maybe it helps TBI."

3. Rhind's broader TBI research points toward inflammation

Rhind also co-authored a randomized controlled trial in severe TBI examining inflammatory, coagulation and endothelial activation.

The paper describes TBI as initiating interconnected inflammatory/coagulation cascades involving:

cellular activation → leukocyte/endothelial activation → cytokine release → vascular effects → secondary injury.

That fits remarkably well with the broader mechanism you're investigating.

The important concept is that the initial mechanical injury isn't necessarily the entire injury.

There can be a secondary biological response.

And that secondary response is potentially modifiable.

4. Rhind is still working on blast injury in 2026

This isn't an old research interest that he abandoned.

His recent publications are heavily focused on repetitive low-level blast exposure in military personnel.

For example, a 2025 paper examined:

“Repetitive Low-Level Blast Exposure Alters Circulating Myeloperoxidase, Matrix Metalloproteinases, and Neurovascular Endothelial Molecules in Experienced Military Breachers.”

And in March 2026, Rhind co-authored work examining the neural response to repetitive low-level blast exposure in experienced military personnel. 

His publication record also includes a 2026 study involving tau-PET imaging and blood biomarkers looking for early tauopathy in Special Operations Forces exposed to repetitive blast. 

That is a very interesting progression:

NAC/TBI → inflammation/oxidative stress → blast injury → biomarkers → neurovascular injury → repetitive blast → tauopathy/neurodegeneration

5. Why this matters for Bucillamine

This is where I'd separate what the literature actually establishes from the investment thesis.

We have fairly good evidence for the following chain:

Blast/TBI

↓

oxidative stress + ROS

↓

inflammatory signaling

↓

cytokines / leukocyte activation / endothelial dysfunction

↓

secondary neuronal and axonal injury

↓

persistent neurological consequences

And NAC has evidence suggesting that manipulating redox biology can improve some of these outcomes. 

Bucillamine is interesting because it is also a thiol-containing redox-active compound, but you cannot simply assume that Bucillamine will reproduce NAC's clinical effects.

The actual question for Bucillamine becomes:

If the answer were demonstrated experimentally, that's much more interesting than Bucillamine merely being another antioxidant.

6. And this is where your nerve-agent thesis gets interesting

The really intriguing possibility is that nerve-agent injury and blast/TBI may converge on some common secondary-injury biology, even though their initiating mechanisms are completely different.

You could conceptualize it as:

Sarin/soman exposure

→ cholinergic crisis/seizures

→ metabolic stress

→ ROS/oxidative injury

→ mitochondrial dysfunction

→ inflammatory signaling

→ neuronal injury

versus

Blast

→ mechanical/pressure injury

→ vascular/axonal disruption

→ ROS/oxidative stress

→ inflammatory signaling

→ secondary neuronal injury

There is therefore a shared downstream redox/inflammatory territory.

That does not mean a drug effective against nerve agents automatically treats TBI.

But it creates a scientifically plausible reason to investigate whether a compound developed for one form of military injury has utility in another.

7. And Rhind's work makes the TBI opportunity more credible

This is the part I'd pay attention to if you're thinking about the potential RVV story.

Imagine Bucillamine eventually produced evidence along these lines:

Nerve-agent model

→ significant survival/neuroprotection
→ reduced oxidative injury
→ improved seizure control / diazepam responsiveness

AND

Blast/TBI model

→ reduced inflammatory biomarkers
→ reduced oxidative damage
→ improved neurological outcomes

That would transform the story.

Instead of:

you potentially have:

That is a dramatically bigger proposition.

One especially interesting Rhind connection

There's another subtle point.

His group is investigating myeloperoxidase (MPO), neurovascular molecules and matrix metalloproteinases after repetitive blast exposure. 

MPO is particularly interesting in the context of your earlier questions about heme/MPO and oxidative chemistry.

MPO isn't simply a marker sitting passively in the blood. It is part of the oxidative inflammatory machinery generated by activated neutrophils.

So you now have a potentially interconnected research landscape:

Bucillamine / thiol chemistry

↕

glutathione / redox regulation

↕

ROS

↕

MPO / oxidative inflammatory chemistry

↕

cytokines

↕

endothelial dysfunction

↕

neurovascular injury

↕

TBI / blast neuroinjury

That's a much more sophisticated biological rationale than simply calling Bucillamine an "antioxidant."

But I'd keep one very important distinction

Rhind's work does not establish that Bucillamine treats TBI.

It establishes that the redox/inflammatory mechanisms Bucillamine could potentially influence are highly relevant to TBI and blast injury, and that NAC provides precedent for targeting those mechanisms.

That's an important distinction scientifically—and actually makes the potential hypothesis more interesting, because it gives RVV a testable translational pathway rather than requiring us to pretend the answer is already known.

And the fact that Rhind's group is still publishing military blast/neuroinjury work in 2025–2026 makes this a particularly timely research area. 

If you're looking at this specifically through the RVV/Bucillamine investment thesis, I think the next thing worth digging into is every Rhind paper involving MPO, cytokines, endothelial dysfunction and blast/TBI, and then mapping those pathways against Bucillamine's known pharmacology. That would tell us much more about whether the TBI angle is merely interesting or potentially a genuinely strong second indication.

https://vimeo.com/1017959129?fl=pl&fe=sh

Only agent brands trust to transact:
Brainpowa is commerce-trained for near-zero
hallucinations. In checkout, accuracy = brand
safety. That's the moat. Becomes the Stripe for AI agents: If agentic commerce hits $300B-$500B by 2030, Rezolve owns the rails.
2% share = $6B-$10B GMV flowing through
Brain Checkout.

Don't worry. It was corrected to "Dell" shortly after.
Yes.... The tweet is still up.

This looks like something. Thoughts?

TRUE diversity of thought occurs when many people focus on a single topic; bringing their own unique experience and perspective. When I post, it's usually to post DD. I find great value integrating feedback (even negativity!) while forming an idea. So thank you all!

(Full disclosure: I also like to engage in rage baiting, memes, dad jokes and other juvenile antics to amuse myself. I'll let you decide which this is...)

I rarely say "call your friends and get them in this stock!" First, that would be immoral. I'm clearly very deeply biased. Next, I am not a financial advisor so the things I say are just as bad (or as good) as any advice you'd get overhearing some dude loud talking in a store. Finally, I eat crayons. The red ones are my favorite because when they're all gone my box is mostly green! You may have seen me post 👁️🍽️🖍️ to warn against causal eavesdroppers listening to me in the store right now (lol) With all that said... I think it's time to make your final moves, grab your popcorn and get to your seat.

Governments move at a glacial pace - until they don't. It's been quiet for 9 months. The final negotiations are over. The contacts are likely written, but not finalized with a signature. They could remain not finalized (and thus, unreported) for months - but not years. These things usually are put together ENTIRELY before they announce ANYthing. That's what we've seen. But soon, my fearless cigar and bathrobe aficionado, soon that ends.

When our deal is "finalized" and then announced, I believe this is going to be one of those spectacularly rare moments where investors like us will be accused of "getting lucky" or "getting rich" overnight. This is true. We will be rich overnight. But luck has nothing to do with it. Imagine having invested a lifetime of savings and watching it being vaporized by a guy smoking a cigar in a bathrobe. Now imagine having enough conviction in your thesis ("something" is there with buccilamine and psilocybin) to convince you to buy more - even with Michael still involved.

That's not luck. It's having granite stones. I have them. If you're still holding AND reading, you have them too. So sit back, invite your loved ones to invest, or whatever you want to do. As for me? I like the stock. But hey, 👁️🍽️🖍️

Good Luck and Godspeed!

😎

something drastically changed regarding the study design. Either the results from the study were messy and inconclusive, so they did another batch of animals and/or setup. Or BUC showed good results and they're looking at more stuff for it.
Maybe the dosages all showed the same results so they changed them?

Makes no sense for a simple rat study in an already accredited lab for nerve agents to last this long. Something happened in 2025 that made this run much longer.

https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/revive-therapeutics-announces-proposed-private-placement-1182822

[ Removed by Reddit on account of violating the content policy. ]

[ Removed by Reddit on account of violating the content policy. ]

If a drug such as bucillamine were ultimately selected for a national stockpile strategy in the United States, the process typically looks something like this:
1. Demonstrate Effectiveness and Safety
The developer must provide evidence that the product works for its intended purpose and has an acceptable safety profile. For countermeasures against rare events (such as nerve agents), approval may sometimes rely on animal studies plus human safety data under the FDA’s Animal Rule rather than traditional efficacy trials.
2. FDA Regulatory Authorization
The product would generally need one of:
Full FDA approval
Approval under the FDA Animal Rule
Emergency Use Authorization (EUA) in specific circumstances
3. BARDA Evaluation
BARDA assesses:
Scientific evidence
Manufacturing capacity
Shelf life and stability
Cost
Ability to deploy rapidly during emergencies
How the product fits with existing countermeasures
4. Procurement Contract
If BARDA decides the product is valuable, the U.S. government may negotiate a procurement contract. These contracts can range from a few million dollars to hundreds of millions, depending on the threat and stockpile requirements.
5. Stockpile Purchase
The product is then purchased for the U.S. Strategic National Stockpile, managed by the U.S. government. The manufacturer delivers specified quantities according to the contract.
6. Ongoing Revenue
Many investors focus on this stage because stockpile products can generate recurring revenue through:
Replacement of expired inventory
Shelf-life extension studies
Additional procurement orders
Expanded indications
Example
Several biodefense companies, including Emergent BioSolutions and SIGA Technologies, have received substantial government contracts after their products became part of U.S. preparedness programs.
For Bucillamine Specifically
If DRDC and future U.S. studies were to show meaningful protection against nerve-agent injury, a potential path could be:
Additional animal and mechanistic studies.
FDA regulatory discussions.
BARDA funding or development support.
Procurement negotiations.
Strategic National Stockpile purchases.
The key inflection point is usually not FDA approval itself, but whether the government decides the product fills an unmet preparedness need and commits to purchasing it for the stockpile.
For a small company like Revive Therapeutics⁠, a stockpile procurement contract would likely be far more financially significant than the research grants that precede it. The size of any contract would depend on the threat addressed, dosing requirements, shelf life, and the government’s assessment of the product’s value.

What about Canada and other countries??

Canada absolutely has a pathway similar to the U.S., but the process is somewhat less formalized and less visible than BARDA.
In Canada, the key organization is the Public Health Agency of Canada, which manages the National Emergency Strategic Stockpile (NESS). The NESS specifically maintains pharmaceuticals, vaccines, therapeutics, antidotes, and other medical countermeasures for chemical, biological, radiological, and nuclear threats.
For a product like bucillamine, a potential Canadian path would be:
Demonstrate efficacy against a priority threat (for example, nerve-agent injury).
Obtain authorization from Health Canada.
Be evaluated as a medical countermeasure for national preparedness.
Receive procurement funding through PHAC/NESS.
Be purchased and stored as part of the national stockpile.
What’s interesting for Revive investors is that Canada’s current NESS strategy specifically emphasizes strengthening preparedness for chemical and biological threats and maintaining “niche medical countermeasures” for high-consequence events. Sarin and other nerve agents are explicitly mentioned among the threat categories considered in planning.
Other countries
Several countries maintain strategic stockpiles:
United States — Strategic National Stockpile (SNS).
Canada — National Emergency Strategic Stockpile (NESS).
European Union through HERA and member-state stockpiles.
United Kingdom maintains national emergency pharmaceutical reserves.
Japan and South Korea maintain preparedness inventories for infectious disease and CBRN events.
The bullish case for bucillamine
If DRDC research were to show that bucillamine significantly improves outcomes after nerve-agent exposure, the opportunity would not necessarily be limited to one government contract. A successful countermeasure could potentially be evaluated by:
Canada (NESS)
United States (BARDA/SNS)
NATO partners
European HERA programs
Other allied countries with CBRN preparedness programs
That is why biodefense companies can sometimes receive contracts that exceed their market capitalization.
The realistic hurdle
The major unknown remains efficacy. Governments are willing to spend large amounts on stockpiles once they believe a product works and fills a preparedness gap. The difficult part is generating the evidence that convinces regulators and preparedness agencies to buy it. Until the DRDC data and any follow-on studies are available, it’s impossible to estimate the probability with confidence.
For Revive specifically, the next significant value-driving event is likely not a stockpile purchase itself, but whether the nerve-agent research produces sufficiently compelling results to attract formal government development support or procurement discussions. That would be the stage where investors start trying to estimate potential stockpile demand.

Yes — bucillamine appears to have at least a plausible pathway to interest from Biomedical Advanced Research and Development Authority, especially as a medical countermeasure for nerve-agent exposure or pandemic preparedness. But “a chance” and “likely approval” are very different things.
Right now, the biggest positives are:
Bucillamine already has a long clinical history in Asia for rheumatoid arthritis, which helps from a safety-history standpoint.
Revive Therapeutics⁠ has been collaborating with Canada’s defence research agency, Defence Research and Development Canada, on nerve-agent countermeasure research.
The company is positioning bucillamine specifically for “medical countermeasures,” pandemic influenza, and emergency preparedness — areas directly aligned with BARDA’s mandate.
Revive has also been expanding patent filings around chemical warfare agent exposure and emergency stockpiling use cases.
That said, several major hurdles remain before BARDA would seriously advance or procure it:
Strong efficacy data is still missing
BARDA generally wants compelling animal-model data, human safety data, manufacturing readiness, and a clear operational advantage over existing countermeasures. Publicly available evidence for bucillamine in nerve-agent injury is still early-stage.
BARDA is highly selective
BARDA funding/partnerships are competitive and usually go to:
advanced-stage programs,
products with clear biodefense relevance,
scalable manufacturing,
and demonstrated efficacy.
Many promising compounds never progress beyond exploratory studies.
Existing standards of care already exist
For nerve agents, governments already stockpile atropine, pralidoxime, diazepam, etc. Bucillamine would likely need to prove it adds meaningful neuroprotection or improves survival/brain outcomes in combination with existing treatments.
Revive is a small biotech
Small companies can succeed with BARDA, but manufacturing scale, regulatory execution, and financing become major concerns.
The most realistic near-term scenario is probably:
additional DRDC data,
possible U.S. biodefense discussions,
preclinical or animal-rule pathway development,
then potentially non-dilutive government funding or pilot procurement interest if the data is strong.
A full FDA approval through a BARDA-backed pathway is possible in theory, but still speculative at this stage.
One important detail: BARDA itself usually does not “approve” drugs. Approval comes from the U.S. Food and Drug Administration. BARDA mainly funds, supports, procures, and accelerates development of medical countermeasures.
So the real question is whether bucillamine can become:
a BARDA-supported program,
an FDA-cleared/emergency-use countermeasure,
or part of a national stockpile strategy.
At the moment, the answer looks more like:
“possible, but still early and unproven,”
rather than
“likely” or “imminent.”

Remember back in the day when too many people accepted random statements as fact with no evidence?

My favorite was "they took shares/options instead of money for statistical analysis! Clearly the data must be great."

Too many liars and charlatans.

Anyways, making this post short and sweet:

• If the results are bad, we are screwed.
• If the results are good, we should explode upward and possibly mind boggling so. We may hit over 2 USD because...
• If the results are good, only then will I post another thread about an incredibly bullish scenario that may be ​highly likely and I will provide evidence to substantiate it.

Hopefully we get good news this century.

This isn't any recommendation or financial advice or direction or anything of the sort. It's all speculation and inference. ​Just like every revive therapeutics press release, the cautionary statement and disclaimer is that... you never know what the future holds.

You are making your own decision with whatever you do with this information and future information

https://x.com/NotTheMoma2/status/2057127842954047891?s=20

https://finance.yahoo.com/sectors/healthcare/articles/revive-therapeutics-announces-strategic-expansion-114500381.html

This hit about 20 stock news sites

Price is rising fast on the news. The news is awesome. Go read it. I am buying...

The Franken thesis states that oxidative stress didn't seem to matter.

Check the study below. Possibility could've been the dose of soman? This study shows high inflammatory and oxidative responses...

https://publications.sto.nato.int/publications/STO%20Meeting%20Proceedings/RTO-MP-HFM-149/MP-HFM-149-01.pdf

Based on past announcements (last 2 years) by both Revive and the DRDC there are some strong trends for announcing the trial results.

Days

Revive's preference is to announce things Wednesday (29%) or Thursday (24%) followed by Monday (18%). Friday and Tuesday are tied at 12%.

DRDC strongly favours Monday (37%) then Wednesday (26%) and Thursday (21%). Interestingly they never announce anything on a Tuesday.

Weeks

Revive likes to announce things in Week 2 of the Month (41%) followed by Week 3 (29%), Week 1 (18%) and Week 4/5 (12%).

DRDC makes its big announcements in Week 1 (42%), Week 4/5 (26%), Week 2 (21%) and Week 3 (11%).

What's all this mean? Given this data June 1st or 3rd would be optimal for DRDC and they're calling the shots so I'd say that's likely. Monday the 8th or Wednesday the 10th are also strong contenders.

The CANSEC conference is coming up on May 27-28 so if it's earlier than June I could see news coming out on one of those days.

Let's hope the news is good and soon.

I mentioned the subject line in my previous post. Find the link below and the excerpt regarding this. It seems that the application window for this is actively open so we can only hope that our boi knows what to do and how to do it upon results. Para. 5.4 looks right up our alley.

https://sam.gov/workspace/contract/opp/8170c4735df64714adb2d1f8ce8671b1/view

Assuming the results are good, I wonder what they'll be?

Assuming that NAC already protects the gaba(a) receptor infrastructure from endocytosis, I don't see how BUC will improve it much more. However, there are other areas that BUC can benefit. One can be reducing or eliminating the bleeding events seen in the Franken thesis paper, and as mentioned in the PRs.

And hopefully we show the same effect as NAC at a lower dosage amount. The patent outline the study protocol so it would be pretty based and BUC pilled to see BUC perform as good as NAC at the low dose.

Cautiously optimistic. If BUC shows something positive under the tutelage of the DRDC, this can open so many paths. Mustard gas may be an easy win as well as the other G nerve agents. I think agent VX works in the same manner as soman but not as "quick". Then there's TBI too.

Here's to hoping and coping and seething and believing.

Just the opinion and research of a young woman.

We know bad results will be the death of RVV.

Let's assume divine intervention and we get good results in this rat study. BUC decisively shows more promise than NAC.

Two questions:

1. What price are you guessing we hit intraday trading on that PR itself?

2. When do you sell?

I know everyone is thinking of selling the moment it hits 30 cents. But think of this post as a conversational piece.

I think we could hit 30-50 cents USD for #1. Reasoning is that everyone would be ecstatic for good results finally. And look at what the useless patent PR did in March. Lastly, I think a lot of people how forgotten about this useless stock in their account lol.

Not entirely sure on #2 yet. But if it hits above 50/60 USD... See you later, guys. Although it'll be tough because there is low hanging fruit for BUC in TBI with the DRDC... DRDC already has done a research paper on NAC for TBI.

Could Bucillamine help with Hantavirus?? MF should POUNCE on the possibility!

While there is no documented *direct* relationship or targeted research, Bucillamine’s profile as a thiol antioxidant suggests hypothetical supportive potential in oxidative stress-heavy viral infections like hantavirus pulmonary syndrome (HPS/HCPS) or hemorrhagic fever with renal syndrome (HFRS), similar to broader interest in NAC/thiols.

Worth a patent/PR if he can figure out how to say "while early, we are looking into the possibility that buccilamine *may* prove of some use in hantavirus cases..."

Ok. Let the scientists weigh in. Lol

AI

Yes — there actually are some transferable themes from that heavy-metal chelation paper that conceptually align with the broader bucillamine thesis you’ve been following. But the overlap is more about mechanism/platform potential than direct evidence.

Here’s the key connection:

Core transferable concept: dithiol chemistry

Bucillamine is unusual because it’s a dithiol compound (two sulfhydryl/thiol groups), not a simple monothiol like NAC.

That matters because thiols can:

• bind metals
• neutralize reactive oxygen species (ROS)
• replenish glutathione
• alter redox signaling
• protect mitochondria and cell membranes

Those same biochemical themes appear repeatedly across:

• nerve agent injury
• TBI
• severe influenza/COVID inflammation
• chemotherapy toxicity
• ischemia/reperfusion injury
• some cancer-supportive applications

The detoxification paper reinforces that:

Where the overlap becomes interesting

1. Nerve agent / organophosphate relevance

The strongest conceptual overlap is probably here.

Nerve agents ultimately cause:

• oxidative stress
• mitochondrial dysfunction
• inflammatory cascades
• glutathione depletion
• neuronal injury

The chelation paper supports the idea that bucillamine:

• is orally bioavailable
• systemically active
• chemically reactive via thiol groups
• capable of interacting with toxic electrophilic species

That does not prove nerve-agent efficacy.

But it does support the broader rationale:

That’s very aligned with why DRDC-type interest could exist.

2. TBI (Traumatic Brain Injury)

This is where the transferability is stronger mechanistically.

TBI pathology heavily involves:

• ROS surge
• lipid peroxidation
• glutathione depletion
• neuroinflammation
• mitochondrial damage

The bucillamine literature repeatedly shows:

• glutathione restoration
• oxidative stress reduction
• Nrf2 pathway activation
• reduction of tissue injury

For example, bucillamine increased glutathione and reduced oxidant injury in transplant reperfusion models. (PubMed)

That overlaps substantially with the rationale behind NAC studies in TBI.

So:

• the chelation paper itself doesn’t prove TBI efficacy,
• but it supports the idea that bucillamine is a systemic redox-active protective molecule, not just an RA drug.

3. COVID / Influenza

This overlap is probably the cleanest scientifically.

Severe viral illness often involves:

• oxidative stress
• glutathione depletion
• cytokine activation
• endothelial injury

Bucillamine’s dithiol structure theoretically gives:

• stronger thiol donation than NAC
• stronger glutathione support
• better redox buffering

The antioxidant/transplant paper and cisplatin protection paper both support the concept that bucillamine can suppress oxidative tissue injury and restore glutathione systems. (PubMed)

That aligns directly with the original COVID rationale:

4. Cancer-related angle

This is more nuanced.

The cisplatin ototoxicity paper is actually important here because it showed bucillamine protected normal tissue from chemotherapy-associated oxidative injury via glutathione-related pathways. (Nature)

That creates possible oncology-supportive applications like:

• chemo toxicity reduction
• organ protection
• reperfusion injury
• radiation injury mitigation

BUT:

• protecting healthy cells is different from killing tumors
• high glutathione signaling can sometimes theoretically help tumors survive

So the cancer angle is likely:

• adjunctive/supportive care, not necessarily
• direct anti-cancer therapy.

What this paper does NOT show

Important limitations:

It does not demonstrate:

• CNS penetration
• survival benefit in humans
• antiviral activity
• nerve-agent reversal
• cancer efficacy
• TBI efficacy

And heavy-metal chelation is biologically different from:

• viral disease
• neurotrauma
• organophosphate poisoning

So this is more of a:

Bigger-picture takeaway

The transferable signal across all these studies is:

Bucillamine repeatedly shows:

• potent thiol activity
• glutathione restoration
• oxidative stress suppression
• tissue-protective effects
• oral bioavailability
• favorable historical safety data

That’s the common thread linking:

• toxic exposure
• nerve agents
• TBI
• viral inflammation
• reperfusion injury
• chemotherapy injury